The new KCE health economics guidelines 2025: how to deal with uncertainties
Join us for an exclusive event dedicated to exploring the upcoming KCE Health Economics (HE) Guidelines for 2025. Discover how these guidelines address key uncertainties and their implications for healthcare decision-making at national and international levels.
| Last name | First name | Organization |
|---|---|---|
| Abdallah | Khadidja | BAYER sa-nv |
| Bily | Caroline | Caroline Bily |
| Block | Sebastien | BLOCK SÉBASTIEN |
| Borgers | Annelies | Janssen-Cilag NV |
| Boydens | Lukas | S.A. NOVO NORDISK PHARMA N.V. |
| Braspenning | Tinne | ISMS |
| Broeckhoven - PhaBio Support | Katleen | Careforceone |
| BV | SHE | SHE BV |
| Cattoir | Céline | - |
| Coppens | Katrien | KS Pharma |
| D'haene | Barbara | LIVV - Two Point Zero Consultancy BV |
| Darquennes | Eline | MSD Europe Belgium SRL |
| De Cock | Roosmarijn | Axes Health BV |
| De Langhe | Sofie | Innosens bv |
| De Smet | Pascale | Insmed Netherlands BV |
| Ghasemi | Nilofar | MENARINI BENELUX NV |
| Heirman | Margino | B. Braun Medical NV |
| Hendrickx | Els | What ELS matters c.v. |
| Khaouiry | Asmae | Axes Health BV |
| Martens | Arne | EA Consultants BV |
| Mergan | Stephanie | HEBIAS bv |
| Minnaert | An-Katrien | Axes Health BV |
| Poirrier | Jean-Etienne | - |
| Present | Erik | Kintiga (AxTalis BV) |
| Rombaut | Toon | Almirall N.V. |
| Theys | Kristof | - |
| Tops | Sven | Kintiga (AxTalis BV) |
| Tsakeu | Elyonore | AbbVie S.A/N.V |
| Van Den Daele | Bart | GILEAD Sciences Belgium bv |
| van Dijck | Patricia | pharma.be VZW |
| Van Hoorenbeeck | Sandra | Janssen-Cilag NV |
| Vandebrouck | Tom | Vandebrouck Coaching and consulting |
| Vandendriessche | Frank | Ficaja Farma |
| Vanderdonck | Frank | Kintiga (AxTalis BV) |
| Vandersmissen | Ine | Janssen-Cilag NV |
| Verheecke | Annouk | Kintiga (AxTalis BV) |
| Wambacq | Liske | Nuwhï |
| Willaert | Marjan | - |
| Wollaert | Lieve | Argenx Benelux |